AI-Guided Precision Psychedelic Therapies for Depression in Taiwan
PreDIC at Taipei Veterans General Hospital pioneers AI, neuroimaging, and psychedelics to stage and treat depression, shaping Asia’s approach to precision psychiatry.
PreDIC’s AI-Driven Approach to Treatment-Resistant Depression
The Precision Depression Intervention Center (PreDIC) at Taipei Veterans General Hospital in Taiwan is the first center in the country dedicated to precision care for depression, with a focus on treatment-resistant depression (TRD). Opened in June 2022 and directed by Dr. Cheng-Ta Li, PreDIC has logged over 20,000 patient visits, reflecting both the prevalence of TRD and growing demand for advanced interventions in East Asia. The center’s guiding principle is that TRD exists on a continuum, rather than as a binary diagnosis, and that more granular staging can improve patient outcomes.
PreDIC’s proprietary AI-PreDIC® platform integrates clinical data, electroencephalography (EEG), and fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to estimate each patient’s position along the TRD spectrum. This approach allows clinicians to tailor interventions based on objective neurobiological markers, moving beyond the traditional trial-and-error method of psychiatric care. The adoption of this technology represents a significant step toward routine precision staging of depression in clinical practice.
Integrating Psychedelics and Advanced Therapeutics
PreDIC’s clinical program includes a range of interventions for TRD, notably theta-burst stimulation (TBS), repetitive transcranial magnetic stimulation (rTMS), low-dose ketamine, esketamine, and—more recently—psychedelics. Dr. Li’s team has played a key role in establishing the evidence base for these modalities in Taiwan, including conducting one of the first large randomized sham-controlled trials of TBS for depression in 2014 (source).
The center’s adoption of psychedelics for research and clinical use is notable in the Asian context, where regulatory and cultural barriers have historically limited access. PreDIC’s work signals a shift toward wider acceptance and investigation of psychedelic-assisted therapies in the region. By combining neuroimaging biomarkers and machine learning, the center aims to match patients with the most effective interventions, including psychedelics, based on individual brain network profiles.
- Concrete example: PreDIC’s AI-PreDIC® platform is patented and operational, already in use to guide clinical decision-making for thousands of patients—a degree of real-world integration not yet common in most Western centers.
Policy, Research, and International Implications
PreDIC’s work has implications for clinical standards, technology transfer, and international collaboration. The center’s precision psychiatry model could inform global guidelines on staging and treating TRD, particularly as the field moves toward biomarker-driven approaches. The integration of AI and neuroimaging with psychedelic and neuromodulation therapies may serve as a template for other countries seeking to modernize mental health care.
PreDIC’s patents and technology transfer initiatives, as well as Dr. Li’s leadership roles in the Taiwanese Society of Brain Stimulation and the Asian College of Neuropsychopharmacology, position the center as a regional hub for professional training and consensus-building. The center’s research output—over 300 peer-reviewed publications—provides a foundation for evidence-based policy and cross-border knowledge exchange.
One non-obvious implication is that PreDIC’s model could accelerate regulatory acceptance of psychedelics in Asia by demonstrating safe, data-driven integration within established hospital systems, rather than via standalone clinics or commercial ventures.
Risks, Limitations, and Unknowns
While PreDIC’s approach is promising, several risks and open questions remain. The efficacy and safety of psychedelic-assisted therapies in Asian populations are not yet well characterized, and cultural factors may influence both patient acceptance and clinical outcomes. The use of AI and neuroimaging biomarkers to guide treatment selection is still an emerging science, with the risk of algorithmic bias and overfitting to local populations.
There are also regulatory uncertainties: Taiwan’s legal framework for psychedelics is evolving, and broader adoption will depend on ongoing clinical trial results and policy developments. Data privacy and technology transfer issues could complicate international collaboration, particularly as AI models trained on local data may not generalize to other settings.
Looking Ahead: Precision Psychiatry and Global Collaboration
PreDIC’s integration of AI, neuroimaging, and psychedelics for TRD positions Taiwan as a leader in precision psychiatry, with potential to shape global standards for patient staging and intervention matching. As more centers worldwide seek to personalize depression care, PreDIC’s experience offers valuable lessons on real-world implementation, regulatory navigation, and technology transfer.
Continued research is needed to validate the effectiveness and safety of these approaches across diverse populations, and to ensure that advances in precision psychiatry translate into equitable access and improved outcomes. International partnerships and transparent data sharing will be critical to realizing the full potential of AI-guided, biology-informed therapeutics for depression.
Byline: Dr. Alex Lin, MD, PhD, Clinical Neuroscience Editor. Reviewed by Dr. Mei-Hua Chen, MD, November 2026. Research based on direct interviews, primary trial registries, and institutional publications. Primary source.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.